Bioregulators Khavinson bioregulator tripeptideNot FDA-approved · research compound

Pinealon

Pinealon (Khavinson)

Evidence: Studied in humans. Example dose: finalize with a provider. Not a fact-check stamp.

1 mg daily SubQ 10-20 day course

10-20 mg Oral Daily

Pineal gland regulatorCNS neuroprotective peptideGene expression modulator

Pinealon (Glu-Asp-Arg) is a Khavinson bioregulator tripeptide that targets the pineal gland and central nervous system. It was developed by Professor Vladimir Khavinson's research group at the St. Petersburg Institute of Bioregulation and Gerontology. Pinealon regulates gene expression in pineal and CNS tissue, supporting melatonin production, circadian rhythm maintenance, and neuroprotective pathways. Like all Khavinson bioregulators, it works at very low concentrations through direct DNA interaction rather than classical receptor binding, and is administered in short intensive courses (10-20 days) followed by extended rest periods of several months.

Quick Start

Route

SubQ injection

Start low

1 mg SubQ

Frequency

10-20 day course

Timing

No fasting required. Evening dosing sometimes preferred for pineal alignment.

Starting dose. 1 mg — Daily

Evening/bedtime preferred (pineal bioregulator). 10-20 day courses.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

1 mg daily · SubQ injection · 10-20 day course

conservative starter

1 mg daily

10-20 day course

Standard

Cerebral Bioregulation (Oral capsule)

10-20 mg · Oral · Daily

anecdotal · community

Synthetic brain bioregulator targeting the cortex and pineal gland interactions. This is the ORAL capsule dose and is not an injection dose. Oral peptide absorption is poor, so this figure is far higher than the injectable protocol on purpose. Do not inject this amount.

10-20 mg

Daily

Reconstitution CalculatorU-100

Vial strength

BAC water

Vials in this mix

Syringe size

Target dose

050100u

Draw to

— units

◆

I will split this dose across more than one syringe

◆

How it works

Pinealon interacts with DNA in pineal gland and CNS cells at the level of histone modification and transcription factor accessibility, modulating expression of genes involved in melatonin synthesis (AANAT, ASMT), circadian clock regulation, and neuroprotective pathways. As a bioregulator, it does not activate traditional cell surface receptors but instead penetrates cells and directly influences gene transcription. The tripeptide structure allows cell penetration and nuclear localization. Effects persist beyond the dosing period because gene expression changes are sustained through epigenetic mechanisms.

What to expect

Early

Days 1–7

Days 1-10 (during course): Sleep improvements may be noticeable. Gene expression changes initiated.

Mid

Weeks 2–4

Weeks 2-8 (after course): Gene expression changes continue to manifest. Sleep benefits persist.

Later

Weeks 4–12

Months: Sustained pineal function improvement. Run next course in 4-6 months.

Evidence

HumanPresent

AnimalPresent

In-vitroPresent

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

The synthetic tripeptide pinealon (Glu-Asp-Arg) demonstrates dose-dependent restriction of reactive oxygen species (ROS) accumulation in cerebellar granule cells, neutrophils, and pheochromocytoma (PC12) cells, induced by oxidative stress stimulated by receptor-dependent or -independent processes.

The synthetic tripeptide pinealon (Glu-Asp-Arg) demonstrates dose-dependent restriction of reactive oxygen species (ROS) accumulation in cerebellar granule cells, neutrophils, and pheochromocytoma (PC12) cells, induced by oxidative stress stimulated by receptor-dependent or -independent processes.

Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation research · 2011 · PMID 21978084

Evidence scope. Cell models under induced oxidative stress; not human subcutaneous dosing evidence.

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Dose/route: 1 mg daily via SubQ injection, 10-20 day course. No checked live PubMed abstract supported this complete molecule/formulation/route/dose/frequency combination.

Primary safety claim: Very well tolerated. No checked live abstract directly established this as the primary concern for the card's exact formulation and regimen.

The honest take

◆

Pineal gland restoration

Russian clinical data supports improved melatonin production and circadian rhythm in elderly. Mechanism (gene expression modulation) is consistent with Khavinson bioregulatory theory.

Neuroprotection

Animal and in vitro data support CNS protective effects. Mechanism involves upregulation of neuroprotective gene programs.

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

◆

Pin alone. Pinealon must not share a syringe with anything else, whatever the pharmacology says. PIN ALONE. Khavinson bioregulator. Gene regulatory signaling at low concentrations requires clean signal.

Documented together

EpithalonBoth target pineal gland. Pinealon supports CNS/pineal gene expression, Epithalon activates telomerase. Run in sequence, not simultaneously.

DSIPPinealon supports pineal/melatonin pathways, DSIP promotes delta sleep. Complementary sleep architecture support.

Keep separate

GHK-CuCopper degrades short bioregulator peptides.

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

Side effects & safety

Commonly reported

Very well tolerated
Mild injection site irritation

Less common & notes

Pinealon is a small tripeptide with excellent safety profile.
No significant adverse events in published literature.
Short course duration limits exposure.

Pharmacokinetics

Illustrative plasma concentration · 2.0 h

Half-life

0.5h

Peak · Tmax

0.05h

Elimination

2.5h

Bioavailability

~100%

SubQ

Duration of action

Weeks to months (epigenetic gene expression changes persist beyond dosing course)

Clearance

Enzymatic degradation (aminopeptidases)

Storage. Standard BAC water 2-8C. 21-28 days stability. Short course means shelf life rarely an issue.

Regulatory status

Not FDA-approved. Available as research peptide. Used in Russian clinical practice. No WADA prohibition.

Put it to work

Calculate, log & track

Open Pinealon straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Pinealon in the app →

Go deeper

The guide & community

The complete Pinealon walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community